When did AtriCure report Q1 2026 earnings?

AtriCure (ATRC) reported Q1 2026 earnings on May 5, 2026 after market close.

What were AtriCure's Q1 2026 revenue and EPS?

AtriCure reported revenue of $141.2M and eps of $0.00 for Q1 2026.

Did AtriCure beat estimates in Q1 2026?

Revenue beat the consensus estimate of $139.7M by $1.5M. EPS beat the consensus estimate of $-0.07 by $0.07.

How did AtriCure's Q1 2026 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 14.3% from $123.6M a year earlier.

Where can I find AtriCure's Q1 2026 SEC filings?

You can read the 8-K earnings release (0001323885-26-000018) and the 10-Q periodic report (0001323885-26-000023) directly on SEC EDGAR. The filing index links above go to sec.gov.

AtriCure ATRC Q1 2026 earnings

Reported May 5, 2026 · After market close

Revenue$141.2MBeat by $1.5M

EPS$0.00Beat by $0.07

Revenue estimate$139.7M

EPS estimate-$0.07

Next report

Date not yet announced

Financials

Q1 2026

Income statement

See full

Revenue$141.2M+14.3%

Gross profit$109.3M+18.0%

Operating income$526.0K+109%

Net income$108.0K+102%

EPS (diluted)$0.00+100%

Balance sheet

See full

Cash & equivalents$146.2M+46.3%

Total debt$76.2M-3.1%

Total equity$491.7M+8.2%

Total assets$644.0M+8.8%

Cash flow

See full

Operating cash flow-$4.0M+63.8%

CapEx$3.9M+76.6%

Free cash flow-$7.8M+40.6%

Valuation & ratios

Valuation

as of 03/31/26

See full

Market cap$1.42B-9.9%

Enterprise value$1.35B-13.1%

P/S2.6×-0.7×

Profitability

See full

Gross margin75.6%+0.8pp

FCF margin9.7%—

Returns & leverage

See full

Debt / equity0.2×0.0×

Current ratio4.3×+0.2×

Segments

By geography

See full

Total International$25.0M+11.5%

Europe$16.1M+13.2%

Asia Pacific$7.1M—

Other International$1.9M+27.2%

By product

See full

Appendage management$60.0M+15.9%

Open ablation$48.6M+14.9%

Pain management$24.3M+27.8%

Minimally invasive ablation$8.3M-20.9%

Versus estimates

Revenue

Q2 2026$153.6MBeat by $1.8M

Q1 2026$141.2MBeat by $1.5M

Q4 2025$140.5MBeat by $785.4K Q3 2025$134.3MMiss by $6.2M Q2 2025$136.1MBeat by $6.0M Q1 2025$123.6MMiss by $7.0M

Diluted EPS

Q2 2026$0.18Beat by $0.18

Q1 2026$0.00Beat by $0.07

Q4 2025$0.06Beat by $0.10 Q3 2025-$0.01Beat by $0.10 Q2 2025-$0.02Beat by $0.13 Q1 2025-$0.14Beat by $0.11

Ask the moment AtriCure reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did AtriCure report Q1 2026 earnings?: AtriCure (ATRC) reported Q1 2026 earnings on May 5, 2026 after market close.
What were AtriCure's Q1 2026 revenue and EPS?: AtriCure reported revenue of $141.2M and eps of $0.00 for Q1 2026.
Did AtriCure beat estimates in Q1 2026?: Revenue beat the consensus estimate of $139.7M by $1.5M. EPS beat the consensus estimate of $-0.07 by $0.07.
How did AtriCure's Q1 2026 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 14.3% from $123.6M a year earlier.
Where can I find AtriCure's Q1 2026 SEC filings?: You can read the 8-K earnings release (0001323885-26-000018) and the 10-Q periodic report (0001323885-26-000023) directly on SEC EDGAR. The filing index links above go to sec.gov.